

# Implementation of Metformin therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

NCT04939935

---

Status	RECRUITING
Phase	Phase 3
Sponsor	The University of Queensland
Enrollment	1,174 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Willing to participate and provide informed consent
- Aged 18-70 years
- Diagnosis of ADPKD based on radiological +/- genetic criteria as per Kidney Health Australia - Caring for Australians and New Zealanders with Kidney Impairment (KHA-CARI) Guidelines
- eGFR equal to or greater than 38 mL/min/1.73m<sup>2</sup> and <90 mL/min/1.73m<sup>2</sup>
- And have either:  
... and 7 more (see full listing online)

### Exclusion (11)

- Diabetes mellitus (as per American Diabetes Association definition), or other systemic conditions that may cause CKD independent of PKD (excluding hypertension)
- Uncontrolled hypertension (Systolic BP >160 mmHg and/or diastolic BP >100 mmHg after a period of rest)
- Clinically significant heart failure, including but not limited to New York Heart Association Class (NYHA) III or IV
- Non-polycystic liver disease, including but not limited to:
- Liver enzymes (ALT, AST or Total Bilirubin) >2 times the upper limit of normal, except when a diagnosis of Gilbert Syndrome exists and/or,  
... and 6 more (see full listing online)

## Locations (49 total)

---

Renal Research, Gosford, New South Wales, Australia  
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia  
Royal North Shore Hospital, Sydney, New South Wales, Australia  
... and 46 more locations

---

<https://clinicaltrials.gov/study/NCT04939935>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).